Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
Leukemia

About this trial
This is an interventional treatment trial for Leukemia focused on measuring recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, relapsing chronic myelogenous leukemia, childhood acute promyelocytic leukemia (M3), blastic phase chronic myelogenous leukemia
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed leukemia of any of the following types: Acute lymphoblastic leukemia Acute myeloid leukemia Chronic myelogenous leukemia in blast crisis Refractory or recurrent disease Immunophenotypic confirmation of disease at initial diagnosis or recurrence More than 25% blasts in the bone marrow (M3) Active extramedullary disease allowed except for leptomeningeal disease No known curative therapy or therapy proven to prolong survival with an acceptable quality of life No active CNS disease PATIENT CHARACTERISTICS: Age 1 to 21 Performance status Karnofsky 50-100% (for patients > 10 years of age) Lansky 50-100% (for patients ≤ 10 years of age) Life expectancy Not specified Hematopoietic WBC < 30,000/mm^3 (hydroxyurea or leukapheresis allowed at the discretion of the principal investigator) Platelet count ≥ 20,000/mm^3 (platelet transfusions allowed) Hemoglobin ≥ 8.0 g/dL (red blood cell transfusions allowed) Hepatic ALT ≤ 5 times upper limit of normal (ULN) Albumin ≥ 2 g/dL Bilirubin ≤ 1.5 times ULN Renal Creatinine normal for age OR Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min/1.73 m^2 Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy At least 7 days since prior biologic therapy, including immunotherapy At least 3 months since prior stem cell transplantation No evidence of active graft-vs-host disease No concurrent biologic therapy No concurrent immunotherapy Chemotherapy Recovered from prior chemotherapy At least 6 weeks since prior nitrosoureas Prior therapy with hydroxyurea allowed for up to 24 hours before initiation of study drug No other concurrent chemotherapy Endocrine therapy Concurrent hydrocortisone or other corticosteroids allowed as premedications prior to blood product transfusions in patients with prior severe allergic reactions Radiotherapy Recovered from prior radiotherapy No concurrent radiotherapy Surgery Not specified Other No other concurrent anticancer agents No other concurrent investigational drugs
Sites / Locations
- Stanford Cancer Center at Stanford University Medical Center
- Indiana University Cancer Center
- Fairview University Medical Center - University Campus
- Mayo Clinic Cancer Center
- University of Mississippi Medical Center
- Herbert Irving Comprehensive Cancer Center at Columbia University
- SUNY Upstate Medical University Hospital
- Cincinnati Children's Hospital Medical Center
- Children's Hospital of Philadelphia
- Children's Hospital of Pittsburgh
- St. Jude Children's Research Hospital
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
- Baylor University Medical Center - Houston
- Children's Hospital and Regional Medical Center - Seattle
- Hospital for Sick Children
- Hopital Sainte Justine
Arms of the Study
Arm 1
Experimental
Temozolomide Therapy